Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: a randomised placebo-controlled double-blind crossover trial
Putananickal N et al.
·
Cephalalgia
Key finding
DL-BHB supplementation at the tested dose did not reduce migraine frequency or intensity versus placebo.
What the study did
Double-blind placebo-controlled crossover trial in 41 adults with episodic migraine. Patients took supplemental DL-beta-hydroxybutyrate or placebo. Migraine days did not improve (mean difference -1.1 days, 95% CI -5.07 to 2.85).
This study used [form], not goBHB. It is shown here as general ketone science. Only goBHB studies back goBHB product claims.